Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Somewhat Bearish -25

Charles River (CRL) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

AI-generated analysis

📉 Analysts predict Charles River (CRL) Q1 earnings of $1.96 per share, marking a 16.2% decline compared to the same quarter last year.

📊 Revenue is forecasted at $971.06 million, reflecting a slight year-over-year decrease of 1.3%.

📉 Over the past 30 days, the consensus EPS estimate has been revised downward by 4.6%, indicating analysts' reassessment of initial projections.

🔍 Earnings estimates show a strong correlation with short-term stock price movements according to empirical studies.

🧪 Revenue from Research Models and Services is expected to reach $208.44 million, down 2.2% year-over-year.

⚙️ Manufacturing Solutions revenue is projected at $187.36 million, representing a 5% increase from the prior-year quarter.

🛡️ Discovery and Safety Assessment revenue is estimated at $587.28 million, with a minor decline of 0.9% from last year.

💰 Non-GAAP operating income for Manufacturing Solutions is forecasted at $45.39 million compared to $41.17 million previously.

🔬 Non-GAAP operating income for Discovery and Safety Assessment is predicted at $129.35 million versus $141.70 million a year ago.

📦 Research Models and Services non-GAAP operating income is estimated at $49.93 million compared to $57.73 million last year.

🧬 Discovery and Safety Assessment operating income (GAAP) is projected at $104.54 million, up from $93.95 million the prior year.

📐 Research Models and Services GAAP operating income stands at an estimated $36.87 million versus $43.61 million last year.

📈 CRL shares have returned +9.4% over the past month, trailing the Zacks S&P 500 composite's +10.3% gain.

🏷️ The stock currently carries a Zacks Rank #3 (Hold), suggesting performance may align with the overall market.

📊 Investors should monitor key metrics alongside headline estimates to fully assess the upcoming earnings report.

Bullish Signals
  • Analysts forecast that revenue from 'Manufacturing Solutions' will reach $187.36 million, representing a positive 5% year-over-year increase compared to the prior quarter.
  • The company's shares have returned +9.4% over the past month, though this outperformed less than the Zacks S&P 500 composite's +10.3% change, indicating reasonable performance relative to the broader market.
  • Operating income for 'Discovery and Safety Assessment' is projected to reach $104.54 million, which compares favorably against the year-ago value of $93.95 million.
  • Charles River currently carries a Zacks Rank #3 (Hold), suggesting performance that may align with the overall market in the near future.
Risk Factors
  • Analyst consensus EPS estimates have been revised downward by 4.6% over the past 30 days, signaling growing pessimism about earnings potential ahead of the quarterly report.
  • Projected total revenue is forecasted to decline 1.3% year-over-year to $971.06 million, with the Research Models and Services segment specifically expected to contract by 2.2%.
  • Operating income forecasts show negative growth across multiple segments: Discovery and Safety Assessment (down 0.9%), Research Models and Services (down 14.3%), and Manufacturing Solutions (flat at $45.39 million vs previous year).
  • The company is predicted to post earnings of $1.96 per share, reflecting an annual decline of 16.2%, indicating potential significant pressure on profitability.
  • Charles River stock has underperformed the broader market recently, gaining only +9.4% compared to the S&P 500's +10.3% gain over the past month.
  • Analysts maintain a Zacks Rank #3 (Hold) rating, suggesting limited confidence in strong outperformance relative to peers.
Full Analysis
Charles River Laboratories International, Inc. (CRL) is set to release its first-quarter earnings report with Wall Street analysts forecasting quarterly EPS of $1.96 per share, which represents a 16.2% decline from the prior year. Revenue is expected to be approximately $971.06 million, marking a slight decrease of 1.3% compared to the same period last year. Over the past 30 days, the consensus EPS estimate has been revised downward by 4.6%, reflecting analysts' reassessment of initial projections as a key factor for predicting short-term stock price movements. Analyst forecasts break down CRL’s performance across its three primary business segments: Research Models and Services, Manufacturing Solutions, and Discovery and Safety Assessment. Revenue from Research Models and Services is projected to be $208.44 million, down 2.2% year-over-year. In contrast, Manufacturing Solutions revenue is expected to reach $187.36 million, a 5% increase, while Discovery and Safety Assessment revenue is forecast at $587.28 million, essentially flat with a -0.9% change. Operating income figures vary by segment and measurement; for instance, Non-GAAP operating income for Manufacturing Solutions is estimated at $45.39 million, compared to $41.17 million in the prior year, whereas Discovery and Safety Assessment Non-GAAP operating income is projected at $129.35 million versus $141.70 million last year. Recent stock performance shows CRL shares gaining 9.4% over the past month, slightly underperforming the Zacks S&P 500 composite which rose 10.3%. The stock currently holds a Zacks Rank of #3 (Hold), suggesting potential alignment with broader market trends in the near future. Investors are urged to monitor earnings revisions and segment-specific metrics as these often drive investor reaction more than headline estimates alone, particularly given the recent downward adjustment in EPS expectations.